Contact the Editorial Desk

Editorial correspondence

Swe Peptider welcomes correspondence on the research record itself: a citation quoted inaccurately, a trial that has since published updated results, a regulatory status change, or a peer-reviewed study on MOTS-c, semaglutide, or tesamorelin that belongs on the references page. This is the category of message this desk is best positioned to act on, and each one is read. This desk does not offer a phone line or live chat; email correspondence keeps a written record that is easier to verify against a cited source, which matters more here than speed of reply.

The most actionable submissions identify the specific page, the exact passage in question, and a supporting reference — a DOI or PubMed identifier where possible — so the proposed change can be checked against its source before anything is revised.

Editorial mailbox: editors@swepeptider.com

What this desk cannot do

So that no message is met with silence for the wrong reason: Swe Peptider is a literature desk, not a clinical service, and it cannot advise on or recommend human use of any compound discussed here; suggest a dose, schedule, or route of administration for any individual; judge whether a cited trial's findings apply to a specific person's situation; or help source, recommend, or locate any compound from any supplier.

Semaglutide and tesamorelin are prescription medicines available only through licensed providers for their approved indications; MOTS-c has no approved human use of any kind. Readers seeking clinical guidance should consult a licensed clinician in their jurisdiction. Responses to editorial correspondence are not guaranteed and the mailbox is monitored intermittently.